Cell Biology: Research & TherapyISSN: 2324-9293

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Cannabis resin extract in Parkinson's disease: Behavioral, Neurochemical, and Histological Evaluation

Cannabis sativa (Family Cannabaceae, L.) has been used in China and India for thousands of years as a medicine. The main active constituents of cannabis are Δ 9 -tetrahydrocannabinol (THC), cannabinol (CBN) and cannabidiol (CBD). Currently, THC and CBD are being carefully used in conditions, such as multiple sclerosis, cancer pain, and chemotherapy associated emesis. The cannabinoid 1 receptor (CB1R) is considered responsible for most THC effects involving sedation, analgesia, hypothermia, catalepsy, and euphoria . CB1Rs are abundantly distributed in the basal ganglia , where they are co-localized with both dopamine (D)1 and 2 receptors on striatonigral dynorphin/substance P and striatopallidal enkephalinergic neuron. In striatum, CB1R is highly expressed in γ-aminobutyric acid (GABA)ergic and glutamatergic presynaptic terminals, where it mediates retrograde endocannabinoid signalling . The inhibition of GABA and glutamate systems in basal ganglia, in turn suppresses D1-mediated effects to exert an anti-dyskinetic action. Additionally, the basal ganglia expresses the cannabinoid 2 receptor (CB2R), particularly in glial cells entailing a role for CB2R-agonists in reducing microglia toxic effects and inflammatory reactions.

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations